COVID-19 antibodies persist, reduce reinfection risk for up to six months: Study

New Delhi, Sep 16 (ANI): A new study has found that most patients with mild COVID-19 infections produce antibodies that persist and protect them from reinfection for up to six months. Individuals with COVID-19 can delay vaccination for 90 days after infection ends. Unvaccinated people who already had COVID-19 were 2.34 times more likely than fully vaccinated people to be infected again. Vaccination provides additional protection against reinfection. Vaccination decreases infectiousness, the risk of hospitalization and deaths from COVID-19, without having the actual infection.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting